58 results about "Vascular resistance" patented technology

The invention provides a multi-source heterogeneous data integrated coronary heart disease accurate prediction method, which comprises the following steps: acquiring various physiological signals of a patient in real time, the physiological signals comprising ST segment change characteristics and basic cycle function parameters in electrocardiosignals, and obtaining a multi-source signal data set; according to the joint data set, analyzing instantaneous fluctuation characteristics of a vascular resistance index in a postprandial hyperlipemia window period, extracting a vascular resistance fluctuation amplitude from the instantaneous fluctuation characteristics, and if it is detected that the fluctuation amplitude exceeds a preset threshold range, marking the window as a high-risk time window; if the score value exceeds a preset threshold value, triggering a coronary heart disease early warning signal according to the comprehensive risk score value in combination with a feature mode of a coronary heart disease hidden period in historical data; and storing the current high-risk time window characteristics and the blood sugar and blood fat curve change trend through a triggered coronary heart disease early warning signal to obtain structured risk archive data.

The invention provides a non-invasive blood pressure estimation method, device and equipment, a storage medium and a product, and belongs to the technical field of biomedicine, and the method comprises the steps that an ECG signal and an ICG signal are preprocessed; generating physiological feature indexes, wherein the physiological feature indexes comprise conventional indexes and special indexes; determining an incidence relation between the conventional index and the basic peripheral vascular resistance parameter as well as the basic artery compliance parameter; inputting the conventional indexes into a pre-trained machine learning model, and outputting basic peripheral vascular resistance prediction parameters and basic artery compliance prediction parameters; performing dynamic correction according to the special indexes, and generating a target peripheral vascular resistance parameter and a target artery compliance parameter; and calculating and generating a blood pressure estimation result. According to the non-invasive blood pressure estimation method, device and equipment, the storage medium and the product, the accuracy, dynamic nature and stability of non-invasive blood pressure estimation can be improved.

The invention provides a patch type thrombus monitoring and NO release closed-loop system for treating venous thrombosis, which comprises a flexible patch substrate on which a sensor module is integrated, and the sensor module comprises a blood flow velocity sensor, a biological impedance sensor, an acceleration sensor and a temperature sensor, the acquisition units are respectively used for acquiring blood flow velocity v at a target vein, related parameters of vascular resistance R, limb movement states and skin temperature of a patch area; the NO release module is used for releasing NO to act on the venous thrombosis part; the control module comprises a signal processing unit and a control unit and is used for receiving the signal output by the sensor module and operating a closed-loop control algorithm to generate an NO release control instruction; and the power supply module provides electric energy for the sensor module, the control module and the NO release module. The invention provides a patch type closed-loop system which integrates thrombus multi-mode monitoring, decision making, NO release assisting and treatment mode self-adaptive switching.

Systems and methods are provided for non-invasively measuring one or more hemodynamic variables using a peripheral arterial region wearable device having a strain sensor and a photoplethysmogram sensor. Different line fit profiles are determined from device collected signals indicative of the strain response versus externally applied cuff pressure and the blood volume and / or the blood circulation changes versus externally applied cuff pressure. From these line fit profiles, external cuff pressure affected line fit features are determined, from which hemodynamic variables for the peripheral arterial region such as blood pressure and / or a systemic vascular resistance are then determined.

The invention relates to wearable multi-modal hemodynamic monitoring equipment and method, and belongs to the technical field of biology and medicine. According to the equipment, more multi-modal physiological signals are acquired from fewer point positions of a human body by using fewer sensors, and hemodynamic parameters including blood flow volume, blood pressure and vascular resistance can be continuously and synchronously monitored through signal processing and parameter calculation. Compared with the prior art, the device has the advantages of being comprehensive in measurement parameter, portable, high in cruising ability, good in man-machine interaction and the like, can be used for long-time and real-time monitoring of hemodynamics, and has important application value and wide application prospects in the aspects of cardiovascular disease diagnosis, chronic disease management, exercise evaluation and the like.

This invention discloses a data processing method and system based on the changing trends of image features, relating to the field of cerebral infarction early warning technology. The data processing method includes: feature extraction: processing image data and modal data separately using feature analysis methods to obtain image features, image feature change data, modal data features, modal data feature change data, and the regions where the features are located. In this invention, image data provides intuitive information about brain structure and lesions, while modal data supplements key features such as hemodynamics, brain tissue electrical activity, and electrical impedance from different physiological dimensions. TCD data can monitor blood flow velocity and vascular resistance in real time, BI data is sensitive to changes in pathological states such as cerebral edema, and EEG data reflects subtle changes in neuronal electrical activity. Through feature extraction and analysis, the combination of multi-source heterogeneous data achieves the correction of image feature changing trends, thereby ensuring the accuracy of data processing.

A method and apparatus of automatically locating in an image of a blood vessel the lumen boundary at a position in the vessel and from that measuring the diameter of the vessel. From the diameter of the vessel and estimated blood flow rate, a number of clinically significant physiological parameters are then determined and various user displays of interest generated. One use of these images and parameters is to aid the clinician in the placement of a stent. The system, in one embodiment, uses these measurements to allow the clinician to simulate the placement of a stent and to determine the effect of the placement. In addition, from these patient parameters various patient treatments are then performed.

The invention relates to the technical field of medical health, and discloses a cardiopulmonary ultrasound assessment method and system for premature infant BPD early warning. The method comprises the steps that premature infant heart rate variability, pulmonary artery systolic pressure and respirator parameter data are synchronously collected through an HL7 FHIR protocol interface, and a BPD early warning basic data set is obtained; performing weighted fusion on the ratio of SDNN to RMSSD, the square ratio of pulmonary artery to systemic circulation systolic pressure and oxygenation parameters in the data through an algorithm to obtain a CPDI value; the CPDI and the cardiopulmonary parameters are combined to evaluate the pulmonary vascular resistance load, and a PVRL index is obtained; the CPDI, the PVRL, the gestational age and the body weight adjustment factor are fused, and a BPD occurrence risk score is obtained; and dividing risk levels according to the scoring interval and generating an early warning result. According to the method, the problem that premature infant BPD early warning lacks cardiopulmonary system multi-parameter fusion analysis and individualized risk assessment in the prior art is solved, and continuous dynamic early warning and accurate risk layering based on CPDI and PVRL indexes are achieved.

The invention discloses a cerebral infarction risk early warning method and system based on an image feature change trend, and relates to the technical field of cerebral infarction early warning. The cerebral infarction risk early warning method comprises the steps of feature extraction, wherein image data and modal data are processed through a feature analysis method, and image features, image feature change data, modal data features, modal data feature change data and regions where the features are located are obtained; the image data provides visual information of a brain structure and a focus, the modal data supplements key features such as hemodynamics, brain tissue electrical activity and electrical impedance from different physiological dimensions, the TCD data can monitor blood flow velocity and vascular resistance in real time, and the BI data is sensitive to change of pathological states such as encephaledema. The EEG data reflects the subtle change of the electrical activity of neurons, and the image feature change trend is corrected through feature extraction and analysis and combination of multi-source heterogeneous data, so that the accuracy of cerebral infarction risk early warning is ensured.

The present invention relates to the field of biomedicine technology, and specifically to mRNA pharmaceutical preparations for treating heart failure, and preparation methods and applications thereof. The present invention delivers mRNA expressing brain natriuretic peptide (BNP) into the body, and utilizes human cells to autonomously express BNP, promote natriuresis and diuresis, relax blood vessels, reduce systemic vascular resistance and plasma volume, thereby achieving the purpose of treating heart failure. The pharmaceutical preparation provided by the present invention has high expression amount and bioavailability, low immunogenicity, short drug onset time, long duration, and is of great significance in maintaining the body's water and salt balance, blood pressure stability, cardiovascular and kidney organ functions, and has great potential in the diagnosis and treatment of heart failure.

An electronic device may comprise a biometric sensor and at least one processor. At least one processor may be configured to obtain a PPG signal through the biometric sensor. At least one processor may be configured to obtain a blood flow rate of a user wearing a wearable electronic device on the basis of the PPG signal. At least one processor may be configured to obtain the blood pressure of the user. At least one processor may be configured to determine cardiovascular resistance indicating a degree to which blood flow is affected in a cardiovascular system of the user based on the obtained blood flow rate and the obtained blood pressure.

A method and apparatus of automatically locating in an image of a blood vessel the lumen boundary at a position in the vessel and from that measuring the diameter of the vessel. From the diameter of the vessel and estimated blood flow rate, a number of clinically significant physiological parameters are then determined and various user displays of interest generated. One use of these images and parameters is to aid the clinician in the placement of a stent. The system, in one embodiment, uses these measurements to allow the clinician to simulate the placement of a stent and to determine the effect of the placement. In addition, from these patient parameters various patient treatments are then performed.

An ischemic cardiopathy diagnosis assistance system includes pressure data acquisition means 11 for acquiring pressure data including proximal pressure Pa in a proximal stenotic segment A1 and distal pressure Pd in a distal stenotic segment A2; intracoronary electrocardiogram data acquisition means 12 for acquiring intracoronary electrocardiogram data made up of a local intracoronary artery electrocardiogram in a neighborhood of the distal stenotic segment; and computational processing means 14 for finding a pressure ratio Pa / Pd between the proximal pressure Pa and distal pressure Pd at a time suitable for diagnosis of ischemic cardiopathy based on these data. The computational processing means temporally associates the pressure data with the intracoronary electrocardiogram data, estimates an analysis period T during which vascular resistance remains stably low from a waveform of the intracoronary electrocardiogram data, and extract the pressure data of the analysis period T, and finds the pressure ratio Pa / Pd from the pressure data.

The present invention belongs to the field of pulmonary vascular disease treatment, and specifically discloses a TGF-β receptor inhibitor for the treatment of pulmonary hypertension. In the rat pulmonary hypertension model induced by monocrotaline (MCT), after using the preparation, the right ventricular systolic pressure (RVSP), right ventricular hypertrophy (Fulton index), pulmonary vascular resistance and vascular wall thickness of the rat can be reversed and reduced, and the survival rate of monocrotaline (MCT)-induced pulmonary hypertension rats can be prolonged. Compared with the modeling group, the expression of IL-17, IL-6 and GM-CSF inflammatory factors in the lung tissue of the preparation-treated group was significantly reduced, and the expression of extracellular matrix-related genes CTGF, Fn1 and Col1α1 also decreased. The preparation can significantly alleviate the pulmonary hypertension in rats induced by monocrotaline (MCT), showing good therapeutic effect and application prospects.

The application discloses a non-invasive continuous real-time blood pressure and hemodynamics and heart function integrated device and a data calculation method thereof, which comprises a signal acquisition module, a statistical and weighted calculation module, a communication module and a display module which are electrically connected with a main control board, wherein the signal acquisition module comprises an ECG and heart sound digitization detection module and a real-time continuous blood pressure and hemodynamics calculation module.The application has the beneficial effects that: the device combines the heart sound and ECG with the non-invasive hemodynamics acquisition device, and the blood pressure parameters obtained by the device are mutually calibrated, so that the device not only solves the problems of real-time continuous blood pressure and hemodynamics detection, but also synchronously outputs ECG parameters, heart sound logarithms, cardiac output, stroke volume, vascular resistance, cardiac contractility and other parameters.

A method of determining a microvascular resistance score indicating perfusion of myocardial tissue in a body of a mammal is provided, comprising obtaining acquired blood pressure data and flow data of blood in a cardiac vessel while the mammal is in a first physiological state; obtaining throughflow data indicative of a geometry the cardiac vessel; generating adjusted blood pressure data and adjusted flow data corresponding to a second physiological state, based on the acquired blood pressure value and the first physiological state; generating the microvascular resistance score, based on the adjusted blood pressure data, the adjusted flow data and the throughflow data; and providing, through an electronic output signal, the microvascular resistance score for display on an electronic display module.

A method and apparatus of automatically locating in an image of a blood vessel the lumen boundary at a position in the vessel and from that measuring the diameter of the vessel. From the diameter of the vessel and estimated blood flow rate, a number of clinically significant physiological parameters are then determined and various user displays of interest generated. One use of these images and parameters is to aid the clinician in the placement of a stent. The system, in one embodiment, uses these measurements to allow the clinician to simulate the placement of a stent and to determine the effect of the placement. In addition, from these patient parameters various patient treatments are then performed.

Methods, systems, and computer-readable medium for determining a systemic vascular resistance (SVR), by receiving a systolic blood pressure (SBP) and a diastolic blood pressure (DBP) from one or more blood pressure devices, receiving a first bioimpedance from a first electrode and a second bioimpedance from a second electrode, determining a stroke volume based on a difference between the first bioimpedance and the second bioimpedance, determining a mean arterial pressure (MAP) based on the SBP and the DBP, receiving a heart rate, determining a cardiac output based on the heart rate and the stroke volume, determining a first value based on a right atrial pressure (RAP) or central venous pressure (CVP) and the map, determining a second value based on the first value and the cardiac output, and determining a SVR based on the second value and a factor.

The application provides application of levosulpiride in preparation of a medicine for treating pulmonary arterial hypertension, and the medicine comprises levosulpiride as an active ingredient. Through a pulmonary arterial hypertension model of a rat, the application gives an intervention treatment of levosulpiride, and the effect of levosulpiride on pulmonary vessels is determined: the levosulpiride can reduce the mean pulmonary arterial pressure of a pulmonary arterial hypertension rat, reduce pulmonary vascular resistance, and improve right ventricle and pulmonary vessel remodeling, thereby providing a strategy for developing the medicine for treating the pulmonary arterial hypertension.

Systems and apparatuses are included that are configured to determine an effectiveness of apparatus and methods used to diagnose and unblock microvascular obstruction (MVO). An infusion system blocks antegrade flow for a short time and measures vascular pressure response as an infusate is infused in stepwise fashion at increasingly higher flow rates. During the antegrade flow occlusion, calculations of a real-time vascular resistance can be obtained using a formula R(t)=(t) / Qmean(t) where: Qmean (t) is flow mean values generated by the infusion system; P(t) is a distal pressure response in a vessel generated from the infusion of the infusate; and R(t) is the calculated real-time vascular resistance using the two other known parameters.

Methods, systems, and computer-readable medium for determining a systemic vascular resistance (SVR), by receiving a systolic blood pressure (SBP) and a diastolic blood pressure (DPB) from a calibrated photoplethysmography (PPG) device, receiving a pulse transit time (PTT) from the PPG device, determining a stroke volume based on the PTT, determining a mean arterial pressure (MAP) based on the SBP and the DBP, receiving a heart rate, determining a cardiac output based on the heart rate and the stroke volume, determining a first value based on a right atrial pressure (RAP) or central venous pressure (CVP) and the map, determining a second value based on the first value and the cardiac output, and determining a SVR based on the second value and a factor.

Compositions for improving metabolic function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, dilates the arteries, decreases blood pressure and systemic vascular resistance, and increases cardiac output. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

The application relates to a coronary microcirculation vascular resistance acquisition method and system based on a layered myocardial model, which comprises the following steps: establishing a coronary vessel model from medical images; generating a side vessel for the coronary artery; regarding the coronary artery and the side vessel as main vessels, fitting and constructing an outer surface of a myocardial model according to the outlet position of the main vessels, establishing an inner surface of the myocardial model based on a similar principle to the outer surface, and ensuring that the volume of the model is the myocardial volume value; using an ellipsoid surface for layered interpolation; selecting a point P in the outermost layer and connecting the main vessel outlet to generate a microcirculation vessel; selecting a point T outside the current layer and cooperating with the nearest microcirculation vessel to generate a bifurcated microcirculation vessel; gradually advancing to the inner layer to form bifurcation and ensure the bifurcation number of each layer; and calculating the resistance value of the main vessel outlet. Compared with the prior art, the application considers the distribution of the coronary artery at various levels of the myocardium under real conditions, so that the calculated resistance value is more accurate and has the specificity of a patient.

The present disclosure provides a system, device, control method and storage medium for simulating physical characteristics of blood vessels. The method for simulating physical characteristics of blood vessels comprises determining blood vessel types of a lesion to be studied, collecting clinical medical data of the lesion blood vessels, performing isolated modeling on each blood vessel branch, setting initial reference values of the model, connecting the blood vessel model and the device for simulating physical characteristics of blood vessels to an in-vitro test device, operating the in-vitro test device based on the initial reference values, and calculating blood vessel resistance, compliance and test temperature in the blood vessel model in real time according to sensor collected data, and calculating differences between target values and corresponding measured values. The in-vitro test device is adjusted through a simulated neural feedback mechanism and a direct coordination mechanism of each blood vessel branch until the differences between the target values and the corresponding measured values meet predetermined conditions.

The application provides a non-invasive blood pressure estimation method, device, equipment, storage medium and product, and belongs to the technical field of biomedicine, wherein the method comprises the following steps: preprocessing an ECG signal and an ICG signal; generating physiological characteristic indexes, and the physiological characteristic indexes comprise conventional indexes and special indexes; determining the correlation between the conventional indexes and basic peripheral vascular resistance parameters and basic arterial compliance parameters; inputting the conventional indexes into a pre-trained machine learning model to output basic peripheral vascular resistance prediction parameters and basic arterial compliance prediction parameters; dynamically correcting the special indexes to generate target peripheral vascular resistance parameters and target arterial compliance parameters; and calculating and generating a blood pressure estimation result. The non-invasive blood pressure estimation method, device, equipment, storage medium and product provided by the application can improve the accuracy, dynamic nature and stability of non-invasive blood pressure estimation.

A method and apparatus of automatically locating in an image of a blood vessel the lumen boundary at a position in the vessel and from that measuring the diameter of the vessel. From the diameter of the vessel and estimated blood flow rate, a number of clinically significant physiological parameters are then determined and various user displays of interest generated. One use of these images and parameters is to aid the clinician in the placement of a stent. The system, in one embodiment, uses these measurements to allow the clinician to simulate the placement of a stent and to determine the effect of the placement. In addition, from these patient parameters various patient treatments are then performed.

The present disclosure belongs to the technical field of biomedicine, and specifically relates to use of a malic enzyme 1 (ME1) inhibitor in preparation of a drug for preventing and treating pulmonary hypertension (PH) and as a marker for detecting and / or treating the PH. Since a protein level and / or an enzymatic activity are significantly increased in a lung tissue, the ME1 can be used as a marker for detecting or treating the PH. Meanwhile, the ME1 inhibitor can ameliorate pulmonary vascular resistance (PVR) and right ventricular involvement / right heart failure in PH patients by reducing a right ventricular systolic pressure (RVSP) and a right ventricular hypertrophy index (RVHI). Therefore, the ME1 inhibitor can be used as a therapeutic target for treating the PH, thereby increasing a medical utility of the ME1 and the ME1 inhibitor.

The invention relates to a monitoring instrument with a blood pressure analysis function, comprising: an acquisition module for continuously acquiring blood pressure and pulse oxygen in real time to obtain a blood pressure wave and a pulse oxygen wave; the data processing module is used for analyzing the characteristic parameters of the blood pressure waves and the pulse oxygen waves to obtain the heart rate, the pulse rate, the stroke volume, the cardiac output, the effective arterial elasticity, the arterial closure pressure, the tissue perfusion pressure and the arterial resistance; the display module is used for displaying the heart rate or the pulse rate, the stroke volume, the cardiac output, the effective artery elasticity, the artery closing pressure and the vascular resistance in real time. By analyzing the characteristic parameters of the blood pressure wave and the pulse oxygen wave and extracting multi-dimensional parameters reflecting the hemodynamic state, including stroke volume, cardiac output, effective arterial elasticity, closing pressure, tissue perfusion pressure and the like, medical staff can be helped to more comprehensively know the circulatory system state of a patient, and the circulatory system state is not limited to basic systolic pressure and diastolic pressure information, so that the medical staff can more comprehensively know the circulatory system state of the patient. And a treatment scheme is timely adjusted and a treatment effect is evaluated.

To provide an agent for the treatment of a patient suffering from pulmonary arterial hypertension (PAH).SOLUTION: An agent for initial triple combination therapy with macitentan, tadalafil, and selexipag for treating a patient having PAH, the agent containing macitentan, tadalafil, and selexipag, wherein the patient has, at initiation of the initial triple combination therapy, a resting mean pulmonary arterial pressure (mPAP) of about 25 mmHg or more, a mean pulmonary arterial wedge pressure (PAWP) of about 15 mmHg or less, and a pulmonary vascular resistance (PVR) of about 240 dyne sec / cm5 or more, and wherein the macitentan and the tadalafil are administered on day 1, and the selexipag is administered within 4 weeks.SELECTED DRAWING: None

Compositions for improving heart function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, provides antiglycation and signaling, which lessens or reduces cardiovascular disease by lessening or preventing atherosclerosis, plaque formation, diastolic dysfunction, systolic dysfunction, fibrosis, and hypertension, and / or by facilitating normal nitric oxide (NO) production, which dilates the arteries, reduces blood pressure and systemic vascular resistance, and increases cardiac output in humans. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function may contain a dietetically or pharmaceutically acceptable carrier and S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate.